Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Optibrium Joins HeCaToS Project and Expands R&D Team

Published: Tuesday, October 08, 2013
Last Updated: Tuesday, October 08, 2013
Bookmark and Share
The Hepatic and Cardiac Toxicity Systems project is a major European project with the objective to efficiently investigate the health impact of compounds on the heart and liver.

In the course of the project, Optibrium will extend and advance its unique quantum mechanical models that predict metabolism by Cytochrome P450 enzymes, while further developments will focus on predicting the formation of reactive or toxic metabolites. The resulting models will be integrated into the HeCaToS system, to determine if metabolites of new compounds may damage the liver and heart, and support the project’s aim to enable the development of safer medications, cosmetics and industrial chemicals.

The EU is providing twelve million Euros for the project, which is co-ordinated by Maastricht UMC+.

Optibrium has recruited new members to its R&D team to facilitate this project and simultaneously accelerate its software development plans. In particular, to lead its contribution to the HeCaToS project, Optibrium has appointed Dr Patrik Rydberg as Associate Director of Computational Chemistry. Patrik joins Optibrium from the Department of Drug Design and Pharmacology at the University of Copenhagen, where he was Associate Professor. As part of the P450 group in this department, Patrik led the development of the SMARTCyp software and undertook pioneering research on the prediction of metabolism. Patrik will also provide leadership on wider research efforts relating to Optibrium’s StarDrop software, adding his extensive computational chemistry experience to the development of this platform that guides the design and selection of high quality compounds in drug discovery. 

Patrik commented, “I am delighted to be joining the Optibrium team and working on the HeCaToS project. This project, with its objective to better predict hepatic and cardiac toxicity, provides an exciting context in which to advance the field of metabolism prediction.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BioSolveIT and Optibrium Sign Collaboration Agreement
Partnership will deliver a link between 2D and 3D design on medicinal chemists’ desktops.
Tuesday, October 20, 2015
Optibrium and Digital Chemistry Announce Technology Collaboration
Integration of bioisostere database with automatic application and prioritisation will guide the identification of successful, novel, high quality compounds in drug discovery.
Friday, December 14, 2012
Optibrium and Cresset Announce Technology Collaboration
Technology exchange combines unique methods for design of novel, high quality compounds in drug discovery.
Thursday, January 05, 2012
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Batten Disease may Benefit from Gene Therapy
NIH-funded animal study suggests one-shot approach to injecting genes.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos